Reduced expression of RECK protein may help differentiate cutaneous malignant melanoma from melanocytic nevus

Anticancer Research

Volumn 35, Issue 6, 2015, Pages 3185-3191

  Zhang, Lei ^a   Xie, Qiang ^b   Shan, Shi Jun ^c   Tabor, Mebratu Ketema ^b   Junkins Hopkins, Jacqueline M ^b  

^a Jiangxi Province Dermatology Hospital   (China)

^b ACKERMAN ACADEMY OF DERMATOPATHOLOGY   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemical stain; Melanoma; Nevus; RECK; Reversion inducing cysteine rich protein with Kazal motifs

Indexed keywords

GLYCOPROTEIN; REVERSIONNINDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESSENGER RNA; RECK PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CELL LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEVUS CELL; PIGMENTED NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; TUMOR INVASION; VERY ELDERLY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; PATHOLOGY;

ADULT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; RNA, MESSENGER;

EID: 84931294675     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tryggvadóttir L, Gislum M, Hakulinen T, Klint A, Engholm G, Storm HH and Bray F: Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 49: 665-672, 2010.
2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
3. Ordóñez NG, Ji XL and Hickey RC: Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 90: 385-390, 1988.
4. Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, Rosai J, Barnhill RL and Jungbluth AA: Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 22: 976-982, 1998.
5. Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, Elder DE and Xu X: Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol 26: 452-457, 2004.
6. Guo R, Franco-Palacios M, Russell M, Goddard L, Hassell L, Gillies E and Fung KM: Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers. Int J Clin Exp Pathol 6: 1658-1664, 2013.
7. Alexander Breslow: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908, 1970.
8. Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P, Fucci M, Pasquini P and Faraggiana T: Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 14: 1218-1223, 1996.
9. Murali R, Hughes MT, Fitzgerald P, Thompson JF and Scolyer RA: Interobserver variation in the histopathologic reporting of key prognosticparameters, particularly clark level, affects pathologic staging of primarycutaneous melanoma. Ann Surg 249: 641-647, 2009.
10. Shoo BA, Sagebiel RW and Kashani-Sabet M: Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 62: 751-756, 2010.
11. Heenan PJ, Matz LR, Blackwell JB, Kelsall GR, Singh A, ten Seldam RE and Holman CD: Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology 8: 717-729, 1984.
12. Brochez L, Verhaeghe E, Grosshans E, Haneke E, Piérard G, Ruiter D and Naeyaert JM: Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 196: 459-466, 2002.
13. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T and Noda M: Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95: 13221-13226, 1998.
14. Rhee JS and Coussens LM: RECKing MMP function: implications for cancer development. Trends Cell Biol 12: 209-211, 2002.
15. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C and Noda M: The membraneanchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789-800, 2001.
16. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID and Sogayar MC: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9: 20, 2009.
17. Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM and Han I: RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res 25: 696-702, 2007.
18. Vernon AE and LaBonne C: Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol 14: R719-721, 2004.
19. Itoh Y, Nagase H: Matrix metalloproteinases in cancer. Essays Biochem 38: 21-36, 2002.
20. Park S, Lee C, Sabharwal P, Zhang M, Meyers CL and Sockanathan S: GDE2 promotes neurogenesis by glycosylphosphatidylinositol-anchor cleavage of RECK. Science 339: 324-328, 2013.
21. Golan K, Vagima Y, Goichberg P, Gur-Cohen S and Lapidot T: MT1-MMP and RECK: opposite and essential roles in hematopoietic stem and progenitor cell retention and migration. J Mol Med (Berl) 89: 1167-1174, 2011.
22. Rabien A, Stephan C, Kilic E, Weichert W, Kristiansen G, Miller K, Jung K and Erbersdobler A: Renal cell neoplasias: reversioninducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. J Transl Med 11: 258, 2013.
23. Wittschieber D, Stenzinger A, Klauschen F, Stephan C, Jung K, Erbersdobler A and Rabien A: Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness. Pathobiology 78: 123-131, 2011.
24. Mao X, Liu L, Zhang B and Zhang D: Reversion-inducing cysteine-rich protein with Kazal motifs gene expression and its clinical significance in peripheral T-cell lymphoma. Oncol Lett 5: 1867-1871, 2013.
25. Stenzinger A, von Winterfeld M, Rabien A, Warth A, Kamphues C, Dietel M, Weichert W, Klauschen F and Wittschieber D: Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer. Hum Pathol 43: 1314-1321, 2012.
26. Jacomasso T, Trombetta-Lima M, Sogayar MC and Winnischofer SM: Downregulation of reversion-inducing cysteine-rich protein with Kazal motifs in malignant melanoma: inverse correlation with membrane-type 1-matrix metalloproteinase and tissue inhibitor of metalloproteinase 2. Melanoma Res 24: 32-39, 2014.
27. Hofmann UB, Westphal JR, Waas ET, Zendman AJ, Cornelissen IM, Ruiter DJ and van Muijen GN: Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP2) correlates with melanoma progression. Br J Cancer 81: 774-782, 1999.
28. Chung TT, Yeh CB, Li YC, Su SC, Chien MH, Yang SF and Hsieh YH: Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. PLoS One 7: e33517, 2012.
29. Lu XX, Zhang SM, Fang Y, Wang ZT, Xie JJ, Zhan Q, Deng XX, Chen H, Jin JB, Peng CH, Li HW and Shen BY: Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Tumour Biol 34: 3339-3343, 2013.
30. Zhang C, Ling Y, Zhang C, Xu Y, Gao L, Li R, Zhu J, Fan L and Wei L: The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci 8: 451-458, 2012.
31. Liu S, Ren S, Howell P, Fodstad O and Riker AI: Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 21: 545-558, 2008.
32. Rabien A, Ergün B, Erbersdobler A, Jung K and Stephan C: RECK overexpression decreases invasive potential in prostate cancer cells. Prostate 72: 948-954, 2012.
33. Lei L, Huang Y and Gong W: Inhibition of miR-92b suppresses non-small cell lung cancer cells growth and motility by targeting RECK. Mol Cell Biochem 387: 171-176, 2014.
34. Lin HY, Chiang CH and Hung WC: STAT3 up-regulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells. Br J Cancer 109: 731-738, 2013.
35. Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, Chen L and Fang L: miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. Oncol Rep. 31: 1357-1363, 2014.
36. Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: MicroRNA-182-5p promotes cell invasion and proliferation by down-regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One 8: e55502, 2013.
37. Qin J and Luo M: MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett 588: 99-104, 2014.